Seroprevalence to herpesviruses in patients with primary brain gliomas
https://doi.org/10.17709/2409-2231-2019-6-4-4
Abstract
Purpose of the study. The purpose of the study was to assess the level of seroprevalence and the frequency of detection of serological markers of acute herpesvirus infection in patients with PGBT in comparison with those in patients with chronic non-tumor diseases.
Materials and methods. Before conducting antitumor therapy, the blood serum of 42 patients with PGBT (the main group) was studied. The comparison group consisted of 137 patients with chronic non-tumor diseases. Antibodies of classes M and G to herpes simplex virus types 1, 2 (HSV-1,2), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus type 6 (HHV-6) were determined by ELISA using JSC "Vector-Best" reagent kits.
Results. Among patients with PGBT, seropositive for HSV-1,2 were 95.2%, CMV — 92.9%, EBV — 100%, HHV-6-40.5% of patients. No statistically significant differences in seroprevalence and the presence of markers of acute infection (IgM) were found either in comparison with non-tumor diseases or depending on the malignancy grade. Antibodies to HSV-1,2, CMV and EBV in patients with gliomas were significantly more often found in the medium range, and in the comparison group — in the high values of coefficient of positivity (CP) for IgG. In all the studied groups, antibodies to HHV-6 were determined statistically significantly less frequently than to other herpes viruses.
Conclusion. The absence of statistically significant differences in seropositivity between groups of patients and their presence between pathogens is most likely a reflection of general trends in the population, and the question of the involvement of various representatives of the Herpesviridae family in neuro-oncogenesis of primary glial brain tumors still remains open.
About the Authors
T. A. ZykovaRussian Federation
Tatiana A. Zykova - MD, PhD, head of the laboratory of virology Rostov Research Institute of Oncology (RRIO).
63 14 line, Rostov-on-Don 344037.
O. I. Kit
Russian Federation
Oleg I. Kit - member Russian Academy of Sciences, MD, PhD, DSc, professor, general director Rostov Research Institute of Oncology (RRIO).
63 14 line, Rostov-on-Don 344037.
E. E. Rostorguev
Russian Federation
Eduard E. Rostorguev - MD, PhD, head of department of neuro-oncology Rostov Research Institute of Oncology (RRIO).
63 14 line, Rostov-on-Don 344037.
E. A. Shevyakova
Russian Federation
Elena A. Shevyakova - biologist laboratory of virology Rostov Research Institute of Oncology (RRIO).
63 14 line, Rostov-on-Don 344037.
N. S. Kuznetsova
Russian Federation
Natalya S. Kuznetsova - oncologist department of neuro-oncology Rostov Research Institute of Oncology (RRIO).
63 14 line, Rostov-on-Don 344037.
References
1. Hawkins C, Croul S. Viruses and human brain tumors: cytomegalovirus enters the fray. J Clin Invest. 2011 Oct;121 (10):3831—3833. DOI: 10.1172/1060005
2. Lin CT, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016 Jul 26; 11(1):32. DOI: 10.1186/s13027-016-0081-x
3. Cobbs С. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 2013 Nov; 25 (6):682-688. DOI: 10.1097/CCO.0000000000000005
4. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar 1; 14(3):246-255. DOI: 10.1093/neuonc/nor227
5. Sjostrom S, Hjalmars U, Juto P, Wadell G, Hallmans G, Tjonneland A, et al. Human immunoglobulin G levels of viruses and associated glioma risk. Cancer Causes Control. 2011 Sep 1; 22 (9):1259-1266. DOI: 10.1007/s10552-011-9799-3
6. Tang KW, Hellstrand K, Larsson E. Absence of cytomegalovirus in high-coverage DNA sequencing of human glioblastoma multiforme. Int J Cancer. 2015; 136(4):977-981. DOI: 10.1002/ijc.29042
7. Yamashita Y, Ito Y, Isomura H, Takemura N, Okamoto A, Motomura K, et al. Lack of presence of the human cytomegalovirus in human glioblastoma. Mod Pathol. 2014 Jul; 27(7):922-929. DOI: 10.1038/modpathol.2013.219
8. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, et al. Landscape of DNA Virus Associations across Human Malignant Cancers — Analysis of 3,775 Cases Using RNA-Seq. J Virol. 2013 Aug 15; 87(16):8916-8926. DOI: 10.1128/JVI.00340-13
9. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro Oncol. 2002 Oct 1; 4(4):278-299. DOI: 10.1093/neuonc/4.4.278
10. Khodak LA, Knizhenko OV, Zakharchenko NM. Herpes virus diseases. Mezhdunarodnyi meditsinskii zhurnal. 2003; 3(9):103-106. (In Russian).
11. Bushtyreva IO, Gaida OV, Kurochka MP, Feoktistova TE, Lebedenko EYu, Kakurina VS, et al. Gestosis trigger mechanisms of realization of the fetus fate. Kubanskii nauchnyi meditsinskii vestnik. 2009; 2 (107):56-59. (In Russian).
12. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008; 113(S7):1953-1968. DOI: 10.1002/cncr.23741
13. Human herpesvirus infections: a guide for doctors. Under the editorship of VA. Isakov. SPb.: Special edition, 2nd edition, revised and expanded. 2013, 670 p. (In Russian). Available at: https://speclit.su/image/catalog/978-5-299-00454-0/978-5-299-00454-0.pdf
14. Vladimirova LYu, Zykova TA, Ryadinskaya LA, Lyanova AA, Shevyakova EA, Bogomolova OA, et al. Impact of viral infection on effectiveness of antitumor treatment for laryngeal cancer. Malignant tumours. 2018; 8(3):49-56. (In Russian). DOI: 10.18027/2224-5057-2018-8-3-49-56
15. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131 (6):803-820. DOI: 10.1007/s00401-016-1545-1
16. Akhtar S, Vranic S, Cyprian FS, Al Moustafa A-E. Epstein-Barr Virus in Gliomas: Cause, Association, or Artifact? Front. Oncol. 2018; 8:123. DOI: 10.3389/fonc.2018.00123
17. Limam S, Missaoui N, Mestiri S, Yacoubi MT, Krifa H, Selmi B, et al. Epstein-Barr virus infection in gliomas. Current Research in Translational Medicine. 2019 Nov 1;67(4):129-133. DOI: 10.1016/j.retram.2019.06.002
18. Piper K, Foster H, Gabel B, Nabors B, Cobbs C. Glioblastoma Mimicking Viral Encephalitis Responds to Acyclovir: A Case Series and Literature Review. Front. Oncol. 2019; 9:8. DOI: 10.3389/fonc.2019.00008
19. Saddawi-Konefka R, Crawford JR. Chronic Viral Infection and Primary Central Nervous System Malignancy. J Neuroimmune Pharmacol. 2010 Sep 1; 5(3):387-403. DOI: 10.1007/s11481-010-9204-0
20. Cuomo L, Trivedi P, Cardillo MR, Gagliardi FM, Vecchione A, Caruso R, et al. Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol. 2001; 63(1):45-51. DOI: 10.1002/1096-9071 (200101)63:1<45:: AID-JMV1006>3.0.CO;2-K
21. Lisyanyi NI, Gnedkova IA, Stanetskaya DN, Rozumenko VD, Kvasha MS, Bel'skaya LN, et al. Connection of human cytomegalovirus and malignant gliomas of brain. Ukrainian Neurosurgical Journal. 2016; 1:44-49. (In Russian).
Review
For citations:
Zykova T.A., Kit O.I., Rostorguev E.E., Shevyakova E.A., Kuznetsova N.S. Seroprevalence to herpesviruses in patients with primary brain gliomas. Research and Practical Medicine Journal. 2019;6(4):45-53. (In Russ.) https://doi.org/10.17709/2409-2231-2019-6-4-4